跳到正文
原文
Nature Medicine· Martin Reck·· 25 天前AI 评分52

MDT-BRIDGE II期临床试验:度伐利尤单抗联合化疗用于可切除或临界可切除非小细胞肺癌术前治疗

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial

AI 导读

MDT-BRIDGE II期临床试验显示,度伐利尤单抗联合化疗用于可切除或临界可切除非小细胞肺癌术前治疗,病理完全缓解率 encouraging。研究指出,对于无法手术的病例可继续化疗联合度伐利尤单抗巩固治疗,未报告新增安全性问题。

正文

Nature Medicine, Published online: 26 October 2026; doi:10.1038/s41591-026-04742-7

As presented at the ESMO Congress 2026: In the global phase 2 MDT-BRIDGE trial, neoadjuvant durvalumab plus chemotherapy in patients with resectable and borderline resectable non-small-cell lung cancer, followed by multidisciplinary reassessment, enabled surgery in most patients, leading to encouraging pathological complete response rates, and no additional safety concerns were reported when patients with unresectable tumors continued with chemoradiotherapy and consolidative durvalumab.

来源:Nature Medicine · nature.com